Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHelios Underw Regulatory News (HUW)

Share Price Information for Helios Underw (HUW)

Share Price is delayed by 15 minutes
Get Live Data
221.00    3.00 (1.38%)
Bid:
220.00
Ask:
222.00
Spread: 2.00 (0.909%)
Market Cap: £150.69m
HUW Live PriceLast checked at - London Stock Exchange

Intraday Helios Underw Share Chart

Update on Share Buyback Programme

Today 07:01

RNS Number : 0528M
Helios Underwriting Plc
13 July 2026
 

13 July 2026

 HELIOS UNDERWRITING PLC

 ("Helios ", or the "Company")

 Update on Share Buyback Programme

 

Helios Underwriting plc, the only publicly traded company offering access to a diverse portfolio of syndicates at Lloyd's of London, the world's largest insurance market, announces an amendment to its share buyback programme in the Company's ordinary shares of 10 pence each ("Ordinary Shares"), launched with Peel Hunt LLP ("Peel Hunt") on 9 April 2026 to return up to a maximum aggregate consideration of £2,000,000 to shareholders (the "Amended Share Buyback Programme").

The Company has to date relied upon the safe harbour conditions for trading set out in Article 5 of the Market Abuse Regulation (596/2014), as it forms part of assimilated law in the UK by virtue of the European Union (Withdrawal) Act 2018 and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019, and in the Commission Delegated Regulation (EU) 2016/1052, as it forms part of assimilated law in the UK and as amended by the FCA's Technical Standards (Market Abuse Regulation) (EU Exit) Instrument 2019 (together, "MAR"). However, due to the illiquidity of the Company's Ordinary Shares, the safe harbour volume parameter has constrained its ability to purchase Ordinary Shares within an efficient and practicable timeframe and the Company has now decided to amend its agreement with Peel Hunt and conduct the Amended Share Buyback Programme on the following basis:

• Peel Hunt will continue to manage the purchases on a discretionary basis, purchasing Ordinary Shares within certain pre-set parameters and making its trading decisions independently of, and uninfluenced by, the Company. Purchases may therefore continue during any closed periods of the Company.

• The Amended Share Buyback Programme will be executed in accordance with the authority to repurchase Ordinary Shares granted by the Company's shareholders at the annual general meeting ("AGM") held on 22 June 2026, being authority to repurchase up to a maximum of 6,942,081 Ordinary Shares (the "General Authority").

• In accordance with the General Authority, the maximum price to be paid per Ordinary Share acquired by the Company pursuant to the Amended Share Buyback Programme will be no more than the higher of (i) 105% of the average middle market closing price of an Ordinary Share on AIM for the five business days preceding the date of purchase and (ii) the higher of the price of the last independent trade and the highest current independent purchase bid for an Ordinary Share on the trading venue where the purchase is carried out; and in any event no more than the net asset value per share of the Company.

• The purchased Ordinary Shares will be held by the Company in treasury at the Company's discretion for later reissue or cancellation. Shares held in treasury are not entitled to dividends and have no voting rights at the Company's general meetings.

• The Amended Share Buyback Programme will continue from the date of this announcement until the earlier of (i) the maximum aggregate consideration of £2,000,000 having been reached and (ii) the expiration of the General Authority or, if earlier, the conclusion of the Company's next AGM.

• Shareholders should be aware that the Amended Share Buyback Programme may on any given trading day represent a significant portion of the daily traded volume in the Company's Ordinary Shares on AIM, and the Company expects daily volumes to exceed 25% of the average daily traded volume in the Ordinary Shares over the 20 trading days preceding a purchase. Accordingly, the Company may not benefit from the exemption contained in Article 5(1) of MAR.

• Outside of the above, the Amended Share Buyback Programme will be conducted in accordance with the other safe harbour parameters as prescribed by MAR insofar as possible.

• As at 10 July 2026, the Company's total issued share capital consisted of 76,040,011 Ordinary Shares, each carrying one voting right, and the Company held 5,945,159 Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 70,094,852, which figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

• The Company confirms that it currently has no unpublished inside information.

 

For further information contact:

Helios Underwriting plc

Louis Tucker - Chief Executive Officer

+44 (0)20 3965 6441

Adhiraj Maitra - Director of Finance and Operations

+44 (0)20 3743 2114

Peel Hunt (Nomad, Broker and Financial Adviser)

Dan Webster / Andrew Buchanan / Martin Frowde

+44 (0)20 7418 8900

Singer Capital Markets (Joint Broker)

Charles Leigh-Pemberton / Russell Cook / James Todd

+44 (0)20 7496 3000

FTI Consulting

Ed Berry

+44 (0)7703 330 199

Christian Harte

+44 (0)7974 288 763

   About Helios

Helios provides a limited liability direct investment into the Lloyd's insurance market and is quoted on the London Stock Exchange's AIM market (ticker: HUW). Helios trades within the Lloyd's insurance market. The portfolio provides a broad spread of business primarily participating in the US and other international wholesale and reinsurance markets. For further information please visit www.huwplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCAKBBPKBKBKOD
Date   Source Headline
28th Sep 20237:00 amRNSHalf Year Results
11th Sep 202311:46 amRNSTransaction in Own Shares
8th Sep 202310:23 amRNSTransaction in Own Shares
8th Sep 20237:00 amRNSTransaction in Own Shares
5th Sep 20233:27 pmRNSTransaction in Own Shares
4th Sep 20233:36 pmRNSTransaction in Own Shares
1st Sep 202311:06 amRNSTransaction in Own Shares
1st Sep 20237:00 amRNSTotal Voting Rights
31st Aug 202311:05 amRNSTransaction in Own Shares
30th Aug 20234:05 pmRNSTransaction in Own Shares
30th Aug 20237:00 amRNSQuarterly Syndicate Mid-Point Forecasts
29th Aug 202312:30 pmRNSTransaction in Own Shares
25th Aug 20232:12 pmRNSTransaction in Own Shares
25th Aug 20237:00 amRNSTransaction in Own Shares
24th Aug 20237:00 amRNSTransaction in own shares
23rd Aug 202311:44 amRNSShare Repurchase Programme
21st Aug 20234:23 pmRNSNotification of Major Holdings
21st Aug 202311:40 amRNSDirector's Shareholding
18th Aug 20238:22 amRNSTransaction in Own Shares
17th Aug 20237:00 amRNSTransaction in Own Shares
15th Aug 20234:30 pmRNSShare Repurchase Programme
2nd Aug 20237:00 amRNSTotal Voting Rights
25th Jul 20237:00 amRNSAcquisition
14th Jul 20237:00 amRNSDirector Dealing
14th Jul 20237:00 amRNSAcquisition of Limited Liability Vehicle
13th Jul 20237:00 amRNSIssue of Equity
4th Jul 20237:00 amRNSResults of Scrip Dividend Election
29th Jun 20233:46 pmRNSDirectorship Change
29th Jun 202311:27 amRNSResults of Annual General Meeting
29th Jun 20237:00 amRNSNotification of Major Holdings
16th Jun 20237:00 amRNSScrip Dividend Reference Price
7th Jun 20233:53 pmRNSDirector’s Shareholding
5th Jun 20233:39 pmRNSFinal Dividend Timetable
5th Jun 20237:00 amRNSDirector’s/PCA Shareholdings
1st Jun 20237:00 amRNSGrant of LTIP Award
31st May 20237:00 amRNSPosting of Annual Report and Notice of AGM
31st May 20237:00 amRNSQuarterly Syndicate Mid-Point Forecasts
26th May 20237:00 amRNSFinal Results
12th May 20237:00 amRNSChange of Adviser
11th May 20237:00 amRNSDirectors' Disclosure
11th Apr 20237:00 amRNSDirector's/PCAs' Shareholding
5th Apr 20237:00 amRNSGrant of LTIP Award and Director Dealing
5th Apr 20237:00 amRNSDirector/PCA Shareholdings
4th Apr 20237:00 amRNSDirectorate Change
4th Apr 20237:00 amRNSQuarterly Syndicate Mid Point Forecasts
10th Jan 20237:00 amRNS2023 Helios Retained Capacity Update
29th Dec 20223:38 pmRNSAcquisitions of LLVs, Issue of Equity and TVR
20th Dec 20227:00 amRNSHolding(s) in Company
19th Dec 202212:06 pmRNSHolding(s) in Company
19th Dec 20229:07 amRNSGrant of LTIP Awards and Directors' Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.